Ubiquitin Biology joint with Targeted Protein Degradation Scientific Organizers: Eric J. Bennett, Nicolas H. Thomä and Niels Mailand Date: March 29 - April 01, 2020
Location: Snowbird Resort, Snowbird, UT, USA For important information on the coronavirus, please click hereProtein ubiquitylation regulates nearly every critical cellular pathway and emerging evidence has demonstrated that defects within the ubiquitin proteasome system can directly lead human disease. This has fueled a recent expansion of drug development efforts to harness the ubiquitin proteasome system to both aid in its functionality during disease progression and to specify individual targets for degradation. Several key questions regarding ubiquitin biology remain unanswered. What are the different mechanisms utilized by ubiquitin pathway enzymes to impart regulatory control over specific cellular pathways? What are the major factors that limit ubiquitin proteasome function during disease pathogenesis? How do infectious diseases impact the ubiquitin system, and can we utilize these diverse mechanisms to develop new tools and paradigms to manipulate the ubiquitin system? Specific goals of the proposed meeting include: 1) Establish detailed connections between the diverse cellular pathways regulated by the ubiquitin system. 2) Determine the structural rules defining how individual proteins are specifically targeted by ubiquitin pathway enzymes. 3) Identify emerging themes used by pathogens to subvert the ubiquitin system. 4) Foster enhanced collaboration between academia and the biotechnology industry toward the goal of developing therapeutics targeting the ubiquitin system. This joint meeting with “Targeted Protein Degradation” will provide a cross-disciplinary understanding of the various genetic and chemical approaches to identify mechanisms to specifically target individual proteins for degradation. One key outcome will be the establishment of collaborations between ubiquitin biologists studying how individual pathways are regulated by ubiquitin and industry leaders developing tools to both activate and inhibit ubiquitin pathway components. Scholarship Deadline: November 21 2019 details
Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.
Registered attendees of one meeting in a joint pair may participate in sessions of the other, pending space availability.
Abstract submission is now closed. Registered attendees may bring a poster onsite. Please contact our office at +1 800-253-0685; +1 970-262-1230 or email info@keystonesymposia.org if you are interested.
We gratefully acknowledge additional support for this conference from:  We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Genentech, Inc.
|